These markers indicate a worse prognosis than CD5-negative DLBCL due to CD5-positive DLBCL and may be involved in early systemic metastasis and progression of the disease stage to refractory status [12–15]. This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.